Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE) | Synapse

⌘+K

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Predictors of Liver Steatosis Progression Among People Living With HIV in Low‐ and Middle‐Income Countries: A Multicentre Longitudinal StudyJournal of the International AIDS Society · 2026
2Metabolic Dysfunction‐Associated Steatohepatitis and the Progression of Cognitive Decline in Older Thai People With HIVJournal of the International AIDS Society · 2026
3Assessing Fidelity to HIV Index Case Testing Protocols in Malawian Clinical Settings: Results From a Cluster Randomized Controlled TrialJournal of the International AIDS Society · 2026
4Cross‐Cutting Implementation Strategies to Integrate Hypertension Care Into HIV Care in Africa: Results From Six Country Studies in the HLB‐SIMPLe AllianceJournal of the International AIDS Society · 2026
5Implementation Outcomes and Lessons From a Health‐Department‐Driven Quality‐Based Financing Approach to HIV Prevention Programmes in New York City, United States: A Mixed Methods AnalysisJournal of the International AIDS Society · 2026

More from Journal of the International AIDS Society

More from GlaxoSmithKline (United States)